The shelf filing confirms IN8bio will need to raise capital within the next 2-3 quarters. Watch for a prospectus supplement (takedown) announcement, which would trigger immediate dilution. The going-concern qualification in the 10-K incorporated by reference is a critical red flag for a $15M market cap stock with no revenue and $5.1M quarterly burn. Any offering is likely to be heavily dilutive at current ~$1.49/share levels.
Price Chart
Executive Summary
IN8bio filed Amendment No. 1 to its existing S-3 shelf registration, maintaining the $200M aggregate offering capacity for common stock, preferred stock, debt securities, warrants, rights, and units. The filing is procedural (updating the prospectus and filing an updated auditor consent), but the shelf overhang is material for a $15M market cap clinical-stage biotech with $21.9M cash, a $5.1M quarterly cash burn, and an auditor going-concern qualification. The 10-Q filed 11 days prior shows cash declining from $27.1M to $21.9M in Q1 2026, with a net loss of $5.1M, confirming the company will need to tap this shelf to fund operations into 2027.
Key Financial Metrics
Key Facts
- S-3/A registers up to $200M in securities; public float is ~$17.6M, limiting near-term sales to ~$5.9M under General Instruction I.B.6 one-third rule
- Cash declined from $27.1M (Dec 2025) to $21.9M (Mar 2026); quarterly net loss of $5.1M implies ~4 quarters of runway without additional financing
- Auditor's report includes a going-concern explanatory paragraph, incorporated by reference into the prospectus
- Q1 2026 EPS of -$0.26 beat consensus of -$0.59, but this is a mechanical artifact of a 7.6x increase in weighted-average shares (2.6M to 19.5M) from prior-year financings, not operational improvement
- Preclinical pipeline programs (INB-300, INB-500) remain paused due to financial constraints; only INB-100 and INB-600 are active
Financial Impact
Shelf capacity of $200M vs $15M market cap; immediate dilution constrained to ~$5.9M under I.B.6, but full shelf represents ~13x current market cap in potential dilution over time
Risk Factors
- Imminent dilutive equity offering given cash burn rate and going-concern qualification
- Full $200M shelf represents extreme potential dilution (~13x current market cap) over time
- Preclinical pipeline paused due to financial constraints limits upside catalysts
- Low stock price ($1.49) means any equity raise will be highly dilutive
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001193125-26-229132 |
| Document: d147989dex231.htm | 0001193125-26-229132 |
| Document: 0001193125-26-229132-index-headers.html | 0001193125-26-229132 |
| Document: 0001193125-26-229132-index.html | 0001193125-26-229132 |
| Document: 0001193125-26-229132.txt | 0001193125-26-229132 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | Press Release | $1.54 $1.04 | ▼ −32.47% | ▼ −34.97% | $0.9799 (−36.37%) |
Jun 1, 2026 21w ago | 8-K | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9799 (+43.36%) |
Jun 1, 2026 21w ago | 424B5 | $1.73 $1.17 | ▲ +32.37% | ▲ +33.60% | $0.9799 (+43.36%) |
May 18, 2026 22w ago | S-3/A | $1.45 $1.18 | ▲ +18.62% | ▲ +24.91% | $0.9799 (+32.42%) |
May 7, 2026 24w ago | 8-K | $1.58 $0.9601 | ▼ −39.23% | ▼ −44.07% | $0.9799 (−37.98%) |
Mar 26, 2026 30w ago | DEFA14A | $1.41 $1.51 | ▲ +7.09% | ▼ −8.97% | $0.9799 (−30.50%) |
Mar 12, 2026 32w ago | Press Release | $1.89 $1.44 | ▼ −23.81% | ▼ −35.42% | $0.9799 (−48.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers